
The Mission
Key Opinion Leaders
International
Advisory Board
Initiatives
Discuss a case
Journal Scan
Latest News
Education Hub
Gallery
IBD Journal Scan
Key articles from high impact journals in last month
November 2020
Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden
Nguyen LH, Örtqvist AK, Cao Y, Simon TG, Roelstraete B, Song M, Joshi AD, Staller K, Chan AT, Khalili H, Olén O, Ludvigsson JF, Published November, 2020 in the Lancet Gastroenterology & Hepatology
Systematic Review on Inflammatory Bowel Disease Patients with Coronavirus Disease 2019: It Is Time to Take Stock
D'Amico F, Danese S, Peyrin-Biroulet L, Published November, 2020 in the Clinical Gastroenterology and Hepatology
Fendrix vs Engerix-B for Primo-Vaccination Against Hepatitis B Infection in Patients With Inflammatory Bowel Disease: A Randomized Clinical Trial
Chaparro M, Gordillo J, Domènech E, Esteve M, Barreiro-de Acosta M, Villoria A, Iglesias-Flores E, Blasi M, Naves JE, Benítez O, Nieto L, Calvet X, García-Sánchez V, Villagrasa JR, Marin AC, Donday MG, Abad-Santos F, Gisbert JP, Published November, 2020 in the American Journal of Gastroenterology
Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID
Chapuis-Biron C, Kirchgesner J, Pariente B, Bouhnik Y, Amiot A, Viennot S, Serrero M, Fumery M, Allez M, Siproudhis L, Buisson A, Pineton de Chambrun G, Abitbol V, Nancey S, Caillo L, Plastaras L, Savoye G, Chanteloup E, Simon M, Dib N, Rajca S, Amil M, Parmentier AL, Peyrin-Biroulet L, Vuitton L; GETAID BioLAP Study Group, Published November, 2020 in the American Journal of Gastroenterology
Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel
Din S, Kent A, Pollok RC, Meade S, Kennedy NA, Arnott I, Beattie RM, Chua F, Cooney R, Dart RJ, Galloway J, Gaya DR, Ghosh S, Griffiths M, Hancock L, Hansen R, Hart A, Lamb CA, Lees CW, Limdi JK, Lindsay JO, Patel K, Powell N, Murray CD, Probert C, Raine T, Selinger C, Sebastian S, Smith PJ, Tozer P, Ustianowski A, Younge L, Samaan MA, Irving PM, Published October, 2020 in the Gut
Fecal Microbiota Alterations Associated With Clinical and Endoscopic Response to Infliximab Therapy in Crohn’s Disease
Xiaojun Zhuang, MD, Zhenyi Tian, MD, Rui Feng, MD, Manying Li, MD, Tong Li, MD, Gaoshi Zhou, MD, Yun Qiu, MD, Baili Chen, MD, Yao He, MD, Minhu Chen, MD, Zhirong Zeng, MD, Shenghong Zhang, MD, Published November, 2020 in the Inflammatory Bowel Diseases Journal
Combination Therapy of Adalimumab With an Immunomodulator Is Not More Effective Than Adalimumab Monotherapy in Children With Crohn’s Disease: A Post Hoc Analysis of the PAILOT Randomized Controlled Trial
Manar Matar, MD, Raanan Shamir, MD, Dan Turner, MD, Efrat Broide, MD, Batia Weiss, MD, Oren Ledder, MD, Anat Guz-Mark, MD, Firas Rinawi, MD, Shlomi Cohen, MD, Chani Topf-Olivestone, MD, Ron Shaoul, MD, Baruch Yerushalmi, MD, Shomron Ben-Horin, MD, Amit Assa, MD, Published November, 2020 in the Inflammatory Bowel Diseases Journa
Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure
Flanagan E, Gibson PR, Wright EK, Moore GT, Sparrow MP, Connell W, Kamm MA, Begun J, Christensen B, De Cruz P, Shelton E, Dowling D, Andrews JM, Brown SJ, Niewiadomski O, Ward MG, Rosella O, Rosella G, Kiburg KV, Ross AL, Bell SJ; PICCOLO Study Group, Published November, 2020 in the Alimentary Pharmacology & Therapeutics
Pre‐treatment magnetic resonance enterography findings predict the response to TNF‐alpha inhibitors in Crohn's disease
Rimola J, Fernàndez-Clotet A, Capozzi N, Rojas-Farreras S, Alfaro I, Rodríguez S, Masamunt MC, Ricart E, Ordás I, Panés J. Pre-treatment magnetic resonance enterography findings predict the response to TNF-alpha inhibitors in Crohn's disease, Published September, 2020 in the Alimentary Pharmacology & Therapeutics